Here’s our weekly round-up of what illnesses are spreading the most in Metro Detroit communities, according to our local ...

AstraZeneca's IL-33-targeting antibody tozorakimab has made the grade in two phase 3 chronic obstructive pulmonary disease (COPD) trials, raising the prospects of a class that has recorded some ...

Airway epithelial cells are frontline sentinels that detect, restrict, and orchestrate immune responses to respiratory viruses. Beyond canonical interferon ...

The first one was that several participants did not know the correct inhaler regimen that they were actively prescribed at ...

So I made a vow, right there in the quiet. Nothing dramatic. Nothing that requires more energy than I have. Just this: Every ...

Coal-fired power generation remains a central component of Sri Lanka’s energy mix, with the Lakvijaya (Norochcholai) Power Plant contributing a substantial share of national electricity production.

The burden of RSV-associated hospitalization was high in older adults, with the greatest risk among the oldest age strata and those with CHF.

Extrafine single-inhaler triple therapy with BDP/FF/GB is effective for improving health-related quality of life and lung function in COPD.

WILMINGTON, DE — AstraZeneca (NYSE: AZN) said its experimental drug tozorakimab reduced moderate-to-severe exacerbations in ...

Sanofi SA SNY on Tuesday reported Phase 2 data for its experimental therapy lunsekimig in chronic respiratory diseases, ...

Friday's positive trial results for tozorakimab mark a significant inflexion point for AstraZeneca PLC (LSE:AZN, NASDAQ:AZN), ...

Positive high‑level results from the phase 3 OBERON and TITANIA trials indicate that tozorakimab achieved statistically significant and clinically meaningful reductions in the a ...